Core Viewpoint - Sichuan Shuangma's stock price experienced a decline of 1.82% on July 30, closing at 19.44 yuan, with a trading volume of 136,800 hands and a transaction amount of 266 million yuan [1][2]. Group 1: Business Overview - Sichuan Shuangma operates in two main sectors: cement building materials and biopharmaceuticals [1]. - The company has two cement production lines with an annual capacity of 2 million tons and two aggregate production lines with an annual capacity of 5 million tons [1]. - In the biopharmaceutical sector, the company, through its subsidiary Hubei Jianxiang, is involved in the raw material pharmaceutical business [1]. Group 2: Recent Developments - Hubei Jianxiang Biopharmaceutical Co., Ltd., a subsidiary of Sichuan Shuangma, recently received the "Export EU Raw Material Drug Certification Document" from the Hubei Provincial Drug Administration, and its liraglutide production line passed the GMP compliance inspection [1]. - This certification is expected to help the company expand into international markets and enhance product competitiveness [1]. - The company has stated that it has not yet participated in the Yarlung Tsangpo River hydropower project [1]. Group 3: Market Activity - On July 30, the main funds for Sichuan Shuangma saw a net outflow of 18.2757 million yuan [2].

Core Viewpoint - Sichuan Shuangma announced that its subsidiary Hubei Jianxiang Biopharmaceutical Co., Ltd. received compliance certificates from the Hubei Provincial Drug Administration, confirming that its production line for the active pharmaceutical ingredient Liraglutide meets GMP standards equivalent to those of the EU and WHO [1] Group 1 - Hubei Jianxiang received the "GMP Compliance Inspection Notification" and "Written Confirmation for Active Substances Exported to EU" from the Hubei Provincial Drug Administration [1] - The A101 production line for Liraglutide at Hubei Jianxiang was inspected and found to comply with China's GMP requirements [1] - The GMP standards met by Hubei Jianxiang are equivalent to those set by the EU, WHO, and ICH Q7 guidelines [1]

（编辑 袁冠琳） 证券日报网讯 四川双马7月30日在互动平台回答投资者提问时表示，未来公司将持续推动核心业务的深 入发展，聚焦于空间大、成长性好、盈利能力良好的生物科技等领域，延伸寻找有协同效应的业务，确 保长期的可持续发展和增长，为股东创造持续的股东回报。若涉及相关情况，公司将根据相关法律法规 及时履行信息披露义务。 ...

证券代码：000935 证券简称：四川双马 公告编号：2025-35 四川和谐双马股份有限公司（以下简称"公司"）控股子公司湖北健翔生物 制药有限公司（以下简称"湖北健翔"）于近期收到了湖北省药品监督管理局出 具的《湖北省药品 GMP 符合性检查告知书》（编号：鄂 GMP 2025-95 号）和《出 口欧盟原料药证明文件》（Written confirmation for active substances exported to EU， 以下简称"WC 证书"）（编号：HB250024）。湖北健翔 A101 车间 A101 生产 线（原料药利拉鲁肽）经湖北省药品监督管理局现场检查，符合中国药品 GMP （即，药品生产质量管理规范）的要求，等同于欧盟、世界卫生组织以及 ICH Q7 （即，国际人用药品注册技术协调会关于原料药的药品生产质量管理规范指南） 药品 GMP 要求。 一、本次通过药品 GMP 检查及获得出口欧盟原料药证明文件（WC 证书） 的具体情况 （一）《湖北省药品 GMP 符合性检查告知书》（编号：鄂 GMP 2025-95 号） 5、检查结论：符合要求 （二）《出口欧盟原料药证明文件》（WC ...

Core Viewpoint - Sichuan Shuangma's subsidiary, Hubei Jianxiang Biopharmaceutical Co., Ltd., has received compliance certificates from the Hubei Provincial Drug Administration, indicating that its production line meets GMP standards equivalent to those of the EU and WHO [1] Group 1 - Hubei Jianxiang has obtained the "Notice of Compliance Inspection for Drug GMP" and "Certificate of Export of Raw Materials to the EU" from the Hubei Provincial Drug Administration [1] - The A101 production line for the raw material drug Liraglutide has passed the on-site inspection and complies with China's GMP requirements [1] - The GMP compliance is recognized as equivalent to the standards set by the EU, WHO, and ICH Q7 guidelines for raw material drug production [1]

Core Viewpoint - Sichuan Shuangma (000935.SZ) announced that its subsidiary Hubei Jianxiang Biopharmaceutical Co., Ltd. has received the GMP compliance inspection notice and EU export certificate from the Hubei Provincial Drug Administration, indicating compliance with international drug production quality management standards [1] Group 1 - Hubei Jianxiang's A101 workshop production line for the raw material drug Liraglutide has passed the on-site inspection by the Hubei Provincial Drug Administration [1] - The compliance with China's GMP standards is equivalent to the requirements set by the EU, World Health Organization, and ICH Q7 guidelines [1]

Group 1 - The company, Sichuan Shuangma (000935.SZ), has stated that it is currently not involved in the Yarlung Tsangpo River hydropower project [1] - The company focuses on the building materials sector, operating two cement production lines and two aggregate production lines [1] - The annual production capacity of the company is 2 million tons of cement and 5 million tons of aggregates, indicating sufficient supply capability [1] Group 2 - The building materials products are sold through a market-oriented sales model, allowing the company to quickly respond to diverse customer needs [1]

建材、水泥概念股集体高开，华新水泥（600801）、中国能建（601868）涨停，西部建设（002302）、 天山股份（000877）、四川双马（000935）、三和管桩（003037）纷纷高开。 ...

Group 1 - The A-share multi-financial sector experienced significant fluctuations and a downward trend, with Nanhua Futures hitting the daily limit down [1] - Other companies such as Hongye Futures, Yong'an Futures, Cuiwei Co., and Sichuan Shuangma also followed the downward trend [1]

Mergers and Acquisitions - Dajia Weikang plans to acquire 60.85% equity of Anhui Dajia Weikang Health Pharmacy for a transaction price of 116 million yuan, making it a subsidiary post-transaction [1] - Jizhong Energy intends to purchase 49% equity of Jingneng Xilin Gol Energy for 669 million yuan, with the target company having a construction scale of 2×660MW efficient supercritical indirect air-cooled units [2] - Bomin Electronics has terminated its acquisition plan for Benchuang Electronics due to failure to reach consensus on key transaction terms [3] Shareholding Changes - Jingbeifang's employee shareholding platform plans to reduce its stake by up to 3% of the company's total shares, equating to a maximum of 26 million shares [4] - Sichuan Shuangma's major shareholders plan to collectively reduce their holdings by up to 2.92% of the company's total shares, amounting to approximately 1.11 million shares [5] - Chenghe Technology's shareholder, Shanghai Kehui Investment, intends to reduce its stake by up to 3% of the company's total shares, which is approximately 564,960 shares [6] Earnings Disclosure - China Merchants Heavy Industry expects a significant decline in net profit attributable to shareholders, projecting a decrease of 90.16% to 91.95%, with an estimated profit of 9 million to 11 million yuan [7] - Dongpeng Beverage anticipates a net profit increase of 33.48% to 41.57%, estimating a profit range of 2.31 billion to 2.45 billion yuan for the first half of 2025 [8] - Shuanglu Pharmaceutical forecasts a substantial net profit growth of 237.95% to 356.24%, estimating a profit of 100 million to 135 million yuan for the first half of 2025, primarily due to changes in the fair value of financial assets [10]